A phase 1/2 trial of BXQ-350 in colorectal cancer, run by Bexion Pharmaceuticals, Inc., active and no longer recruiting.
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma is a phase 1/2 interventional study registered as NCT05322590 by Bexion Pharmaceuticals, Inc., with 195 participants enrolled, started 2023-01-09 and due to reach its primary completion in 2026-04. Interventions recorded: BXQ-350.
Shares ICON plc and the tag pipeline.
Shares ICON plc and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.